Inovio Pharmaceuticals Inc (INO)

[Tamtam]

INOVIO has PENNVAX®-GP in development to prevent and treat HIV strains present in Africa, Asia, Europe, and North America. It has been optimized to target two env antigens, as well as gag and pol antigens. This comprehensive targeting gives PENNVAX-GP the potential to provide global coverage against HIV-1 subtypes. Using a $25 million contract from the NIH, PENNVAX-GP entered into a Phase 1 clinical study in 2015. In addition, INOVIO and academic collaborators, including University of Pennsylvania, University of Massachusetts, Emory University, and Duke University, received a $16 million grant from the NIAID to test various approaches using PENNVAX-GP in preclinical models.